Reduced-intensity conditioning regimen with fludarabine/melphalan versus sequential melphalan, fludarabine and total body irradiation conditioning in acute myeloid leukemia patients with active leukemia or measurable residual disease

被引：0
|
作者：
Lindner, S. [1 ]
Lohmeyer, J. [1 ]
Schlipfenbacher, V. [1 ]
Nguyen, N. T. T. [1 ]
Weber, B. [1 ]
Toenges, R. [1 ]
Riemann, J. [1 ]
Pfeifer, H. [1 ]
Ajib, S. [1 ]
Berg, T. [1 ]
Lang, F. [1 ]
Martin, H. [1 ]
Serve, H. [1 ]
Bug, G. [1 ]
机构：
[1] Univ Klin Frankfurt, Frankfurt, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P992
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [1] Fludarabine and Melphalan Reduced Toxicity Versus a Myeloablative Fludarabine and Busulfan Conditioning Regimen for Acute Myeloid Leukemia
    Mathews, Vikram
    Kulkarni, Uday
    Selvarajan, Sushil
    Joshi, Nutan Damodar
    Fouzia
    Korula, Anu
    Lionel, Sharon Anbumalar
    Lakshmi, Kavitha M.
    Srivastava, Alok
    George, Biju
    Abraham, Aby
    BLOOD, 2023, 142
  • [2] Intensified conditioning with fludarabine/melphalan plus total body irradiation for acute myeloid leukemia with minimal residual or active disease
    Lindner, Sarah
    Lang, Fabian
    Berg, Tobias
    Riemann, Julia
    Jedlickova, Zuzana
    Gueller, Saskia
    Toenges, Rosa
    Steinmann, Juliane
    Martin, Hans
    Serve, Hubert
    Bug, Gesine
    BONE MARROW TRANSPLANTATION, 2018, 53 : 277 - 278
  • [3] Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease
    Blackmon, Amanda
    Afkhami, Michelle
    Yang, Dongyun
    Mokhtari, Sally
    Samara, Yazeed
    Pourhassan, Hoda
    Ball, Brian
    Salhotra, Amandeep
    Agrawal, Vaibhav
    Sandhu, Karamjeet
    Desai, Amrita
    Otoukesh, Salman
    Arslan, Shukaib
    Amanam, Idoroenyi
    Koller, Paul
    Tinajero, Jose
    Aribi, Ahmed
    Aldoss, Ibrahim
    Becker, Pamela
    Artz, Andy
    Ali, Haris
    Stein, Anthony
    Smith, Eileen
    Pullarkat, Vinod
    Forman, Stephen J.
    Marcucci, Guido
    Nakamura, Ryotaro
    Al Malki, Monzr M.
    BONE MARROW TRANSPLANTATION, 2025, 60 (02) : 165 - 174
  • [4] Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
    Baron, Frederic
    Labopin, Myriam
    Peniket, Andy
    Jindra, Pavel
    Afanasyev, Boris
    Sanz, Miguel A.
    Deconinck, Eric
    Nagler, Arnon
    Mohty, Mohamad
    CANCER, 2015, 121 (07) : 1048 - 1055
  • [5] Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan
    Takuya Yamashita
    Akiyoshi Takami
    Naoyuki Uchida
    Takahiro Fukuda
    Tetsuya Eto
    Souichi Shiratori
    Shuichi Ota
    Takashi Akasaka
    Shigesaburo Miyakoshi
    Tadakazu Kondo
    Michihiro Hidaka
    Junya Kanda
    Yoshiko Atsuta
    Shingo Yano
    Bone Marrow Transplantation, 2020, 55 : 1955 - 1965
  • [6] Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan
    Yamashita, Takuya
    Takami, Akiyoshi
    Uchida, Naoyuki
    Fukuda, Takahiro
    Eto, Tetsuya
    Shiratori, Souichi
    Ota, Shuichi
    Akasaka, Takashi
    Miyakoshi, Shigesaburo
    Kondo, Tadakazu
    Hidaka, Michihiro
    Kanda, Junya
    Atsuta, Yoshiko
    Yano, Shingo
    BONE MARROW TRANSPLANTATION, 2020, 55 (10) : 1955 - 1965
  • [7] Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen
    Woods, Ashley C.
    Joseph, Nisha
    Rupji, Manali
    Liu, Yuan
    Langston, Amelia
    Waller, Edmund K.
    BLOOD, 2019, 134
  • [8] Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
    Kekre, Natasha
    Marquez-Malaver, Francisco J.
    Cabrero, Monica
    Pinana, Jl
    Esquirol, Albert
    Soiffer, Robert J.
    Caballero, Dolores
    Terol, M. J.
    Martino, Rodrigo
    Antin, Joseph H.
    Lopez-Corral, L.
    Solano, Carlos
    Armand, Philippe
    Perez-Simon, Jose A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1808 - 1815
  • [9] Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia
    Dhere, Vishal
    Edelman, Scott
    Waller, Edmund K.
    Langston, Amelia
    Graiser, Michael
    Connolly, Erin C.
    Switchenko, Jeffrey M.
    Esiashvili, Natia
    Khan, Mohammad K.
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 837 - 843
  • [10] Melphalan Dose in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation with Reduced-Intensity Fludarabine and Melphalan
    Harada, Kaito
    Machida, Shinichiro
    Yanada, Masamitsu
    Kanamori, Heiwa
    Onizuka, Makoto
    Ozawa, Yukiyasu
    Kobayashi, Hikaru
    Sawa, Masashi
    Kanda, Junya
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Yano, Shingo
    BLOOD, 2017, 130
12345